Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms

Immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1/PD-L1 to boost tumor-specific T lymphocyte immunity have opened up new avenues for the treatment of various histological types of malignancies, with the possibility of durable responses and improved survival. However, the development of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bin, Han, Yin, Zhang, Yuyu, Zhao, Qin, Wang, Huanhuan, Wei, Jinlong, Meng, Lingbin, Xin, Ying, Jiang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311815/
https://www.ncbi.nlm.nih.gov/pubmed/37386520
http://dx.doi.org/10.1186/s13578-023-01073-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311815/
https://www.ncbi.nlm.nih.gov/pubmed/37386520
http://dx.doi.org/10.1186/s13578-023-01073-9

Ejemplares similares